PAHC PHIBRO ANIMAL HEALTH CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 1069899 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.1%
TTM net income YoY51.5%
TTM EPS YoY49.7%
Revenue 3-yr CAGR16.4%
Net income 3-yr CAGR70.5%
Margins
Gross margin33.8%
Operating margin12.5%
Net margin6.7%
FCF margin1.4%
EBITDA margin15.9%
Returns
ROE28.2%
ROA7.1%
ROIC (approx.)15.6%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets72.4%
Debt / equity1.46x
Current ratio3.20x
Interest coverage4.18x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio1.2%
Payout ratio19.0%
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $1.52B | $1.30B |
| Cost of revenue | $1.01B | $896.27M |
| Gross profit | $512.51M | $399.94M |
| R&D expense | $24.55M | $23.73M |
| SG&A expense | $318.12M | $289.48M |
| Operating income | $194.40M | $110.47M |
| Interest expense | $46.42M | $37.22M |
| Pretax income | $137.35M | $67.99M |
| Income tax | $37.63M | $19.73M |
| Net income | $99.72M | $48.26M |
| EBITDA | $245.91M | $156.07M |
| EPS (basic) | 2.46 | 1.19 |
| EPS (diluted) | 2.43 | 1.19 |
| Dividends declared per share | 0.48 | 0.48 |
| Weighted avg. shares (diluted) | 40.96M | 40.68M |
| Balance sheet | ||
| Cash & equivalents | $61.42M | $68.04M |
| Short-term investments | $20.57M | $9.00M |
| Receivables | $238.79M | $227.98M |
| Inventory | $534.88M | $444.43M |
| Current assets | $935.51M | $810.61M |
| PP&E, net | $369.17M | $354.69M |
| Goodwill | $60.05M | $59.65M |
| Intangibles | $30.05M | $36.47M |
| Total assets | $1.50B | $1.36B |
| Current liabilities | $316.47M | $293.47M |
| Short-term debt | $25.02M | $16.25M |
| Long-term debt | $591.77M | $615.43M |
| Total debt | $616.79M | $631.68M |
| Total liabilities | $1.12B | $1.08B |
| Shareholders' equity | $385.48M | $285.68M |
| Net debt | $555.38M | $563.65M |
| Cash flow statement | ||
| Operating cash flow | $68.95M | $80.12M |
| Capital expenditure | $59.09M | $38.29M |
| Free cash flow | $9.87M | $41.83M |
| Investing cash flow | -$71.45M | -$288.69M |
| Financing cash flow | -$6.56M | $207.13M |
| Depreciation & amortization | $51.51M | $45.60M |
| Stock-based compensation | $1.60M | $717,000 |
| Dividends paid | $19.46M | $19.45M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.